Immunotherapy cocktail aims to boost breast cancer remission before surgery
NCT ID NCT04373031
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding an immunotherapy drug called IRX 2 to standard pembrolizumab (Keytruda) and chemotherapy can improve outcomes for people with triple-negative breast cancer. The study involves 12 participants who receive the combination before surgery. The main goal is to see if more patients have no cancer left at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) and IRX 2
What this could lead to
If successful, this combination could increase the chance of eliminating all visible cancer before surgery in triple-negative breast cancer patients.
What could go wrong
This is a small, early-phase trial with only 12 participants, so results may not apply widely. The added immunotherapy may also increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States